• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Prediction for HCC development and the effect of statin for NASH patients

Research Project

Project/Area Number 16K19940
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Digestive surgery
Research InstitutionKumamoto University

Principal Investigator

HIGASHI Takaaki  熊本大学, 医学部附属病院, 非常勤診療医師 (70594878)

Project Period (FY) 2016-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords非アルコール性脂肪肝炎(NASH) / 非アルコール性脂肪性肝疾患(NAFLD) / 肝細胞癌 / 発癌予測 / 186 gene signature / スタチン / メタボリックシンドローム / Gene Signature / 薬剤感受性
Outline of Final Research Achievements

Hepatocellular carcinoma (HCC) are developed from the background livers such as viral hepatitis, alcoholic hepatitis, the non-alcoholic steatohepatitis (NASH) fatty liver disease (NAFLD), but the mechanism of HCC development and progress is still unclear. In this study, I focused on NASH and NAFLD patients in particular to identify the carcinogenic risk of HCC and biomarker poor-prognosis for NASH and NAFLD. And also I tried to search a drug (statin in particular) which might improve the prognosis.
It was confirmed that 186 gene signature was useful for the HCC prediction of the NASH, NAFLD patients. In addition, I confirmed statin could induce the apoptosis and have the anti-proliferative effects on HCC cell lines in vitro. In clinical cohort, the patients who took statin showed significantly longer disease free survival than ones who didn’t take statin.

Report

(3 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • Research Products

    (5 results)

All 2018 2017 2016

All Journal Article (5 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 5 results)

  • [Journal Article] In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment.2018

    • Author(s)
      Hirschfield H, Bian CB, Higashi T, Nakagawa S, Zeleke TZ, Nair VD, Fuchs BC, Hoshida Y.
    • Journal Title

      Exp Mol Med.

      Volume: 50(1) Issue: 1 Pages: e419-e419

    • DOI

      10.1038/emm.2017.164

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Cell type-specific pharmacological kinase inhibition for cancer chemoprevention.2018

    • Author(s)
      Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, Ruiz de Galarreta M, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, Lujambio A, Sanchez R, Fuchs BC, Poelstra K, Prakash J, Hoshida Y.
    • Journal Title

      Nanomedicine.

      Volume: 14(2) Issue: 2 Pages: 317-325

    • DOI

      10.1016/j.nano.2017.11.004

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Hepatic stellate cells as key target in liver fibrosis.2017

    • Author(s)
      Higashi T, Friedman SL, Hoshida Y
    • Journal Title

      Adv Drug Deliv Rev.

      Volume: 121 Pages: 27-42

    • DOI

      10.1016/j.addr.2017.05.007

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.2016

    • Author(s)
      Nakagawa S, Higashi T, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Baba H, Mahajan M, Nair VD, Lanuti M, Iavarone M, Colombo M, Llovet JM, Tager AM, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y, et al.
    • Journal Title

      Cancer Cell

      Volume: 30(6) Issue: 6 Pages: 879-890

    • DOI

      10.1016/j.ccell.2016.11.004

    • Related Report
      2016 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma.2016

    • Author(s)
      Higashi T, Hayashi H, Kitano Y, Yamamura K, Kaida T, Arima K, Taki K, Nakagawa S, Okabe H, Nitta H, Imai K, Hashimoto D, Chikamoto A, Beppu T, Baba H.
    • Journal Title

      Med Oncol.

      Volume: 33(11) Issue: 11 Pages: 123-123

    • DOI

      10.1007/s12032-016-0845-6

    • Related Report
      2016 Research-status Report
    • Peer Reviewed

URL: 

Published: 2016-04-21   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi